Advanced search
1 file | 516.03 KB

Immunological and angiogenic markers during metronomic temozolomide and cyclophosphamide in canine cancer patients

Sofie Denies (UGent) , Laetitia Cicchelero E (UGent) , Hilde De Rooster (UGent) , Sylvie Daminet (UGent) , Ingeborgh Polis (UGent) , Isabel Van de Maele (UGent) and Niek Sanders (UGent)
Author
Organization
Abstract
Metronomic chemotherapy stimulates the immune response via depletion of regulatory T cells (Tregs) and suppresses angiogenesis by modulating the secretion of thrombospondin-1 (TSP-1) and vascular endothelial growth factor (VEGF). In this study, blood was collected from 10 healthy dogs and from 30 canine cancer patients before and 2 and 4weeks after treatment with metronomic temozolomide (6.6mgm−2), cyclophosphamide (12.5mgm−2) or cyclophosphamide and temozolomide. The percentage of circulating CD25+Foxp3+CD4+ Tregs and the plasma levels of TSP-1 and VEGF were measured. There was a significant difference in the percentage of Tregs between cancer patients and healthy dogs. A significant decrease in Tregs was noted in patients treated with metronomic cyclophosphamide and the combination. Treatment with temozolomide had no effect on the percentage of Tregs. TSP-1 and VEGF levels were, respectively, significantly lower and higher in cancer patients than in healthy dogs, but they were not influenced by any of the studied metronomic treatment regimens.
Keywords
temozolomide, cyclophosphamide, regulatory T cells, TSP-1, REGULATORY T-CELLS, LOW-DOSE CYCLOPHOSPHAMIDE, ENDOTHELIAL GROWTH-FACTOR, ORAL MALIGNANT-MELANOMA, PERIPHERAL-BLOOD, FUNCTIONAL-CHARACTERIZATION, CD4(+) CD25(+), HEALTHY DOGS, VEGF LEVELS, CHEMOTHERAPY

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 516.03 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Denies, Sofie, Laetitia Cicchelero E, Hilde De Rooster, Sylvie Daminet, Ingeborgh Polis, Isabel Van de Maele, and Niek Sanders. 2017. “Immunological and Angiogenic Markers During Metronomic Temozolomide and Cyclophosphamide in Canine Cancer Patients.” Veterinary and Comparative Oncology 15 (2): 594–605.
APA
Denies, Sofie, Cicchelero E, L., De Rooster, H., Daminet, S., Polis, I., Van de Maele, I., & Sanders, N. (2017). Immunological and angiogenic markers during metronomic temozolomide and cyclophosphamide in canine cancer patients. VETERINARY AND COMPARATIVE ONCOLOGY, 15(2), 594–605.
Vancouver
1.
Denies S, Cicchelero E L, De Rooster H, Daminet S, Polis I, Van de Maele I, et al. Immunological and angiogenic markers during metronomic temozolomide and cyclophosphamide in canine cancer patients. VETERINARY AND COMPARATIVE ONCOLOGY. 2017;15(2):594–605.
MLA
Denies, Sofie, Laetitia Cicchelero E, Hilde De Rooster, et al. “Immunological and Angiogenic Markers During Metronomic Temozolomide and Cyclophosphamide in Canine Cancer Patients.” VETERINARY AND COMPARATIVE ONCOLOGY 15.2 (2017): 594–605. Print.
@article{7156827,
  abstract     = {Metronomic chemotherapy stimulates the immune response via depletion of regulatory T cells (Tregs) and suppresses angiogenesis by modulating the secretion of thrombospondin-1 (TSP-1) and vascular endothelial growth factor (VEGF). In this study, blood was collected from 10 healthy dogs and from 30 canine cancer patients before and 2 and 4weeks after treatment with metronomic temozolomide (6.6mgm\ensuremath{-}2), cyclophosphamide (12.5mgm\ensuremath{-}2) or cyclophosphamide and temozolomide. The percentage of circulating CD25+Foxp3+CD4+ Tregs and the plasma levels of TSP-1 and VEGF were measured. There was a significant difference in the percentage of Tregs between cancer patients and healthy dogs. A significant decrease in Tregs was noted in patients treated with metronomic cyclophosphamide and the combination. Treatment with temozolomide had no effect on the percentage of Tregs. TSP-1 and VEGF levels were, respectively, significantly lower and higher in cancer patients than in healthy dogs, but they were not influenced by any of the studied metronomic treatment regimens.},
  author       = {Denies, Sofie and Cicchelero E, Laetitia and De Rooster, Hilde and Daminet, Sylvie and Polis, Ingeborgh and Van de Maele, Isabel and Sanders, Niek},
  issn         = {1476-5810},
  journal      = {VETERINARY AND COMPARATIVE ONCOLOGY},
  keyword      = {temozolomide,cyclophosphamide,regulatory T cells,TSP-1,REGULATORY T-CELLS,LOW-DOSE CYCLOPHOSPHAMIDE,ENDOTHELIAL GROWTH-FACTOR,ORAL MALIGNANT-MELANOMA,PERIPHERAL-BLOOD,FUNCTIONAL-CHARACTERIZATION,CD4(+) CD25(+),HEALTHY DOGS,VEGF LEVELS,CHEMOTHERAPY},
  language     = {eng},
  number       = {2},
  pages        = {594--605},
  title        = {Immunological and angiogenic markers during metronomic temozolomide and cyclophosphamide in canine cancer patients},
  url          = {http://dx.doi.org/10.1111/vco.12203},
  volume       = {15},
  year         = {2017},
}

Altmetric
View in Altmetric
Web of Science
Times cited: